

## CORRECTIONS

**Brott TG, Halperin JL, Bacharach JM, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery Developed in Collaboration With the American Academy of Neurology and Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol* 2011;57:e16–94; <http://dx.doi.org/10.1016/j.jacc.2010.11.006>.**

In Section 5.1, the second item of the bulleted list beginning “Indications for carotid duplex sonography follow,” (p. e31), “Follow-up of known stenosis (>20%) in asymptomatic individuals,” “(>20%)” was changed to “(>50%).” It now reads, “Follow-up of known stenosis (>50%) in asymptomatic individuals.”

<http://dx.doi.org/10.1016/j.jacc.2012.06.006>

**Frelinger III AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers. *J Am Coll Cardiol* 2012;59:1304–11.**

There was an error in the number of subjects in Group 4 in Table 1. The correct table is printed below.

**Table 1** Summary of Demographic and Baseline Characteristics for All PPI Groups

Characteristic	PPI Group 1: Lansoprazole (n = 40)	PPI Group 2: Dexlansoprazole (n = 40)	PPI Group 3: Omeprazole (n = 40)	PPI Group 4: Esomeprazole (n = 40)	Overall (n = 160)
Sex					
Male	20 (50.0%)	20 (50.0%)	20 (50.0%)	20 (50.0%)	80 (50.0%)
Female	20 (50.0%)	20 (50.0%)	20 (50.0%)	20 (50.0%)	80 (50.0%)
Age (yrs)	32.8 ± 6.48 (20–47)	35.7 ± 7.92 (22–53)	34.0 ± 7.40 (22–51)	33.3 ± 7.10 (20–49)	33.9 ± 7.26 (20–53)
Race					
White	40 (100.0%)	39 (97.5%)	39 (97.5%)	39 (97.5%)	157 (98.1%)
American Indian or Alaska Native	0	0	1 (2.5%)	1 (2.5%)	2 (1.3%)
Native Hawaiian or Other Pacific Islander	0	1 (2.5%)	0	0	1 (0.6%)
Ethnicity					
Hispanic or Latino	40 (100.0%)	38 (95.0%)	38 (95.0%)	40 (100.0%)	156 (97.5%)
Not Hispanic or Latino	0	2 (5.0%)	2 (5.0%)	0	4 (2.5%)
Weight (kg)	70.1 ± 10.29	70.8 ± 9.95	68.6 ± 7.44	71.6 ± 10.83	70.3 ± 9.69
Height (cm)	164.3 ± 8.91	165.0 ± 8.49	162.3 ± 8.40	164.3 ± 8.73	163.9 ± 8.61
BMI (kg/m <sup>2</sup> )	25.9 ± 2.26	26.0 ± 2.41	26.1 ± 2.16	26.4 ± 2.50	26.1 ± 2.32

Values are n (%) or mean ± SD (range).

BMI = body mass index; PPI = proton pump inhibitor.